Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
Year: 2022
Type: article
Study design: Observational Study
Abstract: The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6-11.5) and 56.8% (95% CI, 56.3-57.3) in the period 8-59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9-80.7) and 86.0% (95% CI, 84.5-87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.
Source: Nature Communications
Authors: Otavio T. Ranzani, Matt D. T. Hitchings, Rosana Leite de Melo, Giovanny V. A. de França, Cássia de Fátima R. Fernandes, Margaret L. Lind, Mario Sergio Scaramuzzini Torres, Daniel Henrique Tsuha, Leticia C. S. David, Rodrigo F. C. Said, Maria Almiron, Roberto D. de Oliveira, Derek A. T. Cummings, Natalie E. Dean, Jason R. Andrews, Albert I. Ko, Julio Croda
Institutions: Universitat Pompeu Fabra, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Fundação Faculdade de Medicina, Barcelona Institute for Global Health, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Instituto do Coração - HCFMUSP, University of Florida Health, University of Florida, Ministério da Saúde, Yale University, Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz, World Health Organization Regional Office for the Americas, Pan American Health Organization (Brasil), Universidade Estadual de Mato Grosso do Sul, Emory University, Stanford University, Instituto Gonçalo Moniz, Universidade Federal de Mato Grosso do Sul
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,890
OpenAlex ID: W4302293777